Targeted Genomic Profiling of Acral Melanoma.
Yeh I, Jorgenson E, Shen L, Xu M, North JP, Shain AH, Reuss D, Wu H, Robinson WA, Olshen A, von Deimling A, Kwok PY, Bastian BC, Asgari MM.
Yeh I, et al.
J Natl Cancer Inst. 2019 Oct 1;111(10):1068-1077. doi: 10.1093/jnci/djz005.
J Natl Cancer Inst. 2019.
PMID: 30657954
Free PMC article.
RESULTS: In addition to BRAF (21.3%), NRAS (27.9%), and KIT (11.5%) mutations, we identified a broad array of MAPK pathway activating alterations, including fusions of BRAF (2.5%), NTRK3 (2.5%), ALK (0.8%), and PRKCA (0.8%), which can be targeted by available inhibitors. I …
RESULTS: In addition to BRAF (21.3%), NRAS (27.9%), and KIT (11.5%) mutations, we identified a broad array of MAPK pathway activating altera …